OverviewSuggest Edit

Allakos, a biopharmaceutical company, focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The Company is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis.
TypePublic
Founded2012
HQRedwood City, US
Websiteallakos.com

Latest Updates

Employees (est.) (Mar 2020)96(+7%)
Job Openings14
Share Price (Nov 2020)$101.5 (+2%)
Cybersecurity ratingBMore

Key People/Management at Allakos

Dan Janney

Dan Janney

Chairman
Robert Alexander

Robert Alexander

Chief Executive Officer, Director
Robert Andreatta

Robert Andreatta

Director
Mark Asbury

Mark Asbury

Chief Legal Officer, General Counsel
Paul Walker

Paul Walker

Director
Steven P. James

Steven P. James

Director
Show more

Allakos Office Locations

Allakos has an office in Redwood City
Redwood City, US (HQ)
975 Island Dr #201
Show all (1)

Allakos Financials and Metrics

Allakos Revenue

USD

Net income (Q2, 2020)

(39.3m)

EBIT (Q2, 2020)

(40.4m)

Market capitalization (17-Nov-2020)

5.3b

Closing stock price (17-Nov-2020)

101.5

Cash (30-Jun-2020)

153.9m

EV

5.2b
Allakos's current market capitalization is $5.3 b.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

General and administrative expense

2.4m3.7m12.4m29.6m

R&D expense

14.7m18.5m33.3m61.9m

Operating expense total

17.1m22.3m45.7m91.4m

EBIT

(17.1m)(22.3m)(45.7m)(91.4m)
Quarterly
USDQ2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

General and administrative expense

2.4m3.3m5.8m5.9m7.5m11.6m12.1m

R&D expense

7.1m8.7m15.1m14.1m16.1m18.3m28.3m

Operating expense total

9.5m12.0m20.9m20.1m23.6m29.9m40.4m

EBIT

(9.5m)(12.0m)(20.9m)(20.1m)(23.6m)(29.9m)(40.4m)
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Cash

13.4m85.2m33.7m38.4m

Prepaid Expenses

150.0k1.0m2.7m4.0m

Current Assets

13.6m86.2m181.6m499.9m

PP&E

333.0k445.0k8.8m8.4m
Quarterly
USDQ2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

19.3m51.6m31.5m36.5m308.8m135.9m153.9m

Prepaid Expenses

3.0m3.6m1.5m1.3m3.1m4.0m3.3m

Current Assets

67.1m197.2m168.7m154.3m520.1m483.8m458.3m

PP&E

3.4m7.6m9.0m8.7m8.4m8.1m7.7m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(17.1m)(23.6m)(43.5m)(85.4m)

Depreciation and Amortization

148.0k241.0k242.0k1.5m

Accounts Payable

(1.1m)510.0k76.0k3.6m

Cash From Operating Activities

(17.6m)(22.6m)(38.4m)(63.0m)
Quarterly
USDQ2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(17.9m)(29.0m)(20.0m)(39.0m)(60.8m)(27.8m)(67.1m)

Depreciation and Amortization

119.0k183.0k357.0k732.0k393.0k

Accounts Payable

(647.0k)915.0k1.3m874.0k1.7m3.1m3.7m

Cash From Operating Activities

(17.4m)(25.8m)(13.3m)(27.7m)(43.9m)(18.6m)(43.7m)
USDFY, 2016

Financial Leverage

-0.4 x
Show all financial metrics

Allakos Cybersecurity Score

Cybersecurity ratingPremium dataset

B

89/100

SecurityScorecard logo

Allakos Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Allakos Online and Social Media Presence

Embed Graph

Allakos News and Updates

Allakos Announces Results from a Phase 1 Study of Subcutaneously Administered Lirentelimab (AK002)

-- Subcutaneous formulation of lirentelimab was safe and well tolerated and demonstrated sustained eosinophil suppression supporting once monthly dosing -- -- Management to host conference call and webcast today at 8:00 am ET --

Allakos Reports Second Quarter 2020 Financial Results and Provides Business Update

REDWOOD CITY, Calif., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell-related diseases, today reported financial results for the second quarter ended June 30, 2020 and provided an …

ROSEN, NATIONAL INVESTOR COUNSEL, Files First Securities Class Action Lawsuit Against Allakos Inc. - ALLK

NEW YORK, March 12, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces it is first to file a class action lawsuit on behalf of purchasers of the securities of Allakos Inc. (NASDAQ: ALLK) between August 5, 2019 through December 17, 2019, inclusive (the "Class...

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Allakos (ALLK) Investors with Who Have Suffered Losses to Contact Its Attorneys: Securities Fraud Class Action Filed

SAN FRANCISCO, March 11, 2020 /PRNewswire/ -- Hagens Berman urges Allakos Inc. (NASDAQ: ALLK) investors who have suffered significant losses to submit their losses now. A securities fraud class action has been filed against the Company and certain investors may have valuable claims. Class...

ROSEN, A LEADING LAW FIRM, Continues to Investigate Securities Claims Against Allakos Inc. - ALLK

NEW YORK, Jan. 17, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Allakos Inc. (NASDAQ: ALLK) resulting from allegations that Allakos may have issued materially misleading business...

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Urges Allakos (ALLK) Investors with Significant Losses to Contact Its Attorneys; Firm Investigating Possible Securities Fraud

SAN FRANCISCO, Dec. 19, 2019 /PRNewswire/ -- Hagens Berman urges Allakos Inc. (NASDAQ: ALLK) investors who have suffered significant losses to submit their losses now or contact the firm immediately to learn if they qualify to recover compensable damages. The firm is investigating Allakos...
Show more

Allakos Blogs

Allakos Reports Third Quarter 2020 Financial Results and Provides Business Update

Allakos Reports Third Quarter 2020 Financial Results and Provides Business Update Content Import Mon, 11/09/2020 - 08:04 Allakos Reports Third Quarter 2020 Financial Results and Provides Business Update November 9, 2020 at 8:01 AM EST This release is a backfil…

Allakos Announces Presentation from its Eosinophilic Gastrointestinal Diseases Program at the American College of Gastroenterology (ACG) 2020 Annual Scientific Meeting

REDWOOD CITY, Calif. , Nov. 02, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, announced a poster presentation at last week’s American College of Gastroenterology 2020

Allakos Announces Pricing of Public Offering of Common Stock

Allakos Announces Pricing of Public Offering of Common Stock Content Import Wed, 10/28/2020 - 20:20 Allakos Announces Pricing of Public Offering of Common Stock October 28, 2020 at 8:20 PM EDT This release is a backfill from a News Wire General …

Allakos Previews Preliminary Financial Results for the Three Months Ended September 30, 2020

REDWOOD CITY, Calif. , Oct. 27, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK) (“Allakos” or “the Company”), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today previewed results for the three months ended September 30, 2020 .

Allakos Announces Publication of Results from the Phase 2 Study of Lirentelimab (AK002) in Patients with Eosinophilic Gastritis and/or Eosinophilic Duodenitis (ENIGMA) in the New England Journal of Medicine

Allakos Announces Publication of Results from the Phase 2 Study of Lirentelimab (AK002) in Patients with Eosinophilic Gastritis and/or Eosinophilic Duodenitis (ENIGMA) in the New England Journal of Medicine Content Import Wed, 10/21/2020 - 17:00 Allakos Announces Publication of Results fro…

Allakos Initiates Patient Recruitment for AK002 Registrational Studies

-- Phase 3 study in eosinophilic gastritis and/or eosinophilic duodenitis and Phase 2/3 study in eosinophilic esophagitis --  -- Top-line safety and efficacy results from both studies expected in the second half of 2021 -- REDWOOD CITY, Calif. , June 03, 2020 (GLOBE NEWSWIRE) -- Allakos Inc.
Show more

Allakos Frequently Asked Questions

  • When was Allakos founded?

    Allakos was founded in 2012.

  • Who are Allakos key executives?

    Allakos's key executives are Dan Janney, Robert Alexander and Robert Andreatta.

  • How many employees does Allakos have?

    Allakos has 96 employees.

  • Who are Allakos competitors?

    Competitors of Allakos include Quellis Biosciences, Nocion Therapeutics and Vyriad.

  • Where is Allakos headquarters?

    Allakos headquarters is located at 975 Island Dr #201, Redwood City.

  • Where are Allakos offices?

    Allakos has an office in Redwood City.

  • How many offices does Allakos have?

    Allakos has 1 office.